Clinical Applications of PD-L1 Bioassays for Cancer Immunotherapy

Authors

Delong Liu, New York Medical CollegeFollow
Shuhang Wang
Wendy Bindeman

Award

NYMC First Author of a research article cited the highest number of times at the 2018 NYMC Faculty Author Celebration

Author ORCID Identifier

0000-0003-4502-4949

DOI

10.1186/s13045-017-0479-y

Journal Title

Journal of Hematology & Oncology

First Page

110

Document Type

Article

Publication Date

5-17-2017

Department

Medicine

Keywords

B7-H1 antigen analysis and genetics, tumor biomarkers analysis and immunology, neoplastic gene expression regulation, immunohistochemistry methods, immunotherapy methods, neoplasms pathology and therapy, programmed cell death 1 receptor immunology, genetics of messenger RNA, human CD274 protein

Disciplines

Medicine and Health Sciences | Neoplasms | Therapeutics

Abstract

Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression as a biomarker of response have been developed for many cancer immunotherapy agents. These assays use a variety of detection platforms at different levels (protein, mRNA), employ diverse biopsy and surgical samples, and have disparate positivity cutoff points and scoring systems, all of which complicate the standardization of clinical decision-making. This review summarizes the current understanding and ongoing investigations regarding PD-L1 expression as a potential biomarker for clinical outcomes of anti-PD-1/PD-L1 immunotherapy.

Recommended Citation

Liu, D., Wang, S., & Bindeman, W. (2017). Clinical Applications of PD-L1 Bioassays for Cancer Immunotherapy. Journal of Hematology & Oncology, 10 (1), 110. https://doi.org/10.1186/s13045-017-0479-y

Publisher's Statement

Originally published in Journal of Hematology & Oncology (2017) 10:110. The original material can be found here.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.